SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced the signing of a new lease at its 530 Fairview Avenue property in Seattle, Washington. A wholly owned subsidiary of Novo Nordisk A/S, a healthcare company and world leader in diabetes care, has agreed to lease 36,900 square feet, anchoring BioMed's recently constructed research facility in Seattle's South Lake Union market.
Commenting on the project, Don Foster, Corporate Vice President of Novo Nordisk, said, "530 Fairview Avenue is an excellent facility that provides us with all of the critical infrastructure that we need to effectively pursue our research, and the South Lake Union market is a tremendous location that enables us to recruit key scientists to help us pursue our goals."
Alan Gold, BioMed's President and Chief Executive Officer, commented, "We are thrilled to forge this new relationship with one of the world's premier healthcare companies. Novo Nordisk's commitment at our 530 Fairview Avenue property is a testament to the strength of South Lake Union -- a critical cluster for the region's preeminent research institutions -- and to BioMed's development team for producing another world-class facility that meets the rigorous requirements of the leading scientific research companies."
About Novo Nordisk
Novo Nordisk A/S is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas such as
hemophilia management, growth hormone therapy and autoimmune inflammation
therapy. Novo Nordisk manufactures and markets pharmaceutical products and
services that make a significant difference to patients, the medical
profession and society. With headquarters i
|SOURCE BioMed Realty Trust, Inc.|
Copyright©2008 PR Newswire.
All rights reserved